Australian Dry Eye

Click here to edit subtitle


Novaliq to study novel dry eye treatment

Posted by australiandryeye on May 13, 2017 at 3:35 AM

Novaliq announced plans to develop a treatment for ocular neuropathic pain and inflammation in individuals with dry eye disease.

The treatment is being developed in collaboration with the University of Cologne, Germany, the company announced in a press release. 

Dry eye disease (DED) with neuropathic ocular pain is frequently underserved, according to Novaliq. Molecules attempting to target the cannabinoid receptor system are often unstable in water-based formulations, but Novaliq’s EyeSol drug delivery system, which takes poorly soluble drugs and turns them into effective therapies, may help with the bioavailability, stability and efficacy of the cannabinoid-receptor targeting agents, the company said.

“Increasing evidence is available on the importance of neuropathic ocular pain in DED. Based on solid results of our ongoing test series we expect a significant impact of Novaliq’s first-in class Nov-07 program in comparison with existing DED drugs on an established DED mouse model,” Philipp Steven, MD, of the Ocular Surface Group at the department of ophthalmology, University of Cologne, Germany, said in the release. 

“We are now translating evidence from our experimental model into final, conformational studies in close cooperation with Novaliq for a phase 1 clinical study in the near future. Based on the preclinical results, we believe that the Nov-07 program will facilitate the treatment of [dry eye disease] utilizing a dual mode of action toward inflammation and ocular neuropathic pain.”

Categories: None

Post a Comment


Oops, you forgot something.


The words you entered did not match the given text. Please try again.

Already a member? Sign In